SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 294,352.56 |
| Enterprise Value ($M) | 358,457.56 |
| Book Value ($M) | 6,821.00 |
| Book Value / Share | 3.86 |
| Price / Book | 43.15 |
| NCAV ($M) | -109,566.00 |
| NCAV / Share | -62.00 |
| Price / NCAV | -2.69 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.07 |
| Return on Assets (ROA) | 0.04 |
| Return on Equity (ROE) | 0.40 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.54 |
| Current Ratio | 0.65 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 27,785.00 |
| Assets | 143,422.00 |
| Liabilities | 137,351.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 9.08 | 1.30 | |
| 13G/A | BlackRock, Inc. | 8.10 | 3.23 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 670,396 | 3,010,018 | 22.27 | |
| 717,489 | 3,904,861 | 18.37 | |
| 808,952 | 5,302,005 | 15.26 | |
| 904,384 | 9,276,102 | 9.75 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ABT – Abbott Laboratories | ADCT – ADC Therapeutics SA |